Introduction {#Sec1}
============

One of modern medicine's greatest achievements has been the production of antimicrobials against disease-causing microbes, but after more than 70 years of widespread use, these therapeutic agents have gradually lost their potency \[[@CR1]\]. Antimicrobial resistance (AMR) is now a serious global health concern causing problems in the treatment and prevention of infections. Nevertheless, these microorganisms especially bacteria, causes some of the most common infections in different settings; in the community, in hospitals or transmitted through the food chain \[[@CR2]\]. Antibiotics are among the most commonly prescribed drugs in hospitals and in developed countries about 30% of the hospitalized patients are treated with these drugs \[[@CR3]\]. Antibiotic use in Africa is progressively on the rise and the availability of un-prescribed antibiotics is part of the problem. A study combining data from various African countries revealed that approximately 90.1% of cases of acute illness sought care outside the home and 36.2% took an antibiotic medication and over 30% of the individuals acquired antibiotics without prescription \[[@CR4]\]. Several studies from various African countries have furthermore shown high levels of antibiotic resistant bacterial pathogens \[[@CR5]--[@CR9]\]. In spite of the ongoing research on antimicrobial resistance, there are still no indications that the situation is abating. In order to formulate an efficient AMR control plan, it is crucial to have a clear view on the current situation so as to determine when, how and where to initiate control measures. The present study assessed a 12 months trend of antimicrobial resistance in clinically relevant bacterial isolates in Accra, Ghana.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

### Study design {#Sec4}

This study was a retrospective analysis of miscellaneous clinical samples that were tested for bacterial presence and subsequent susceptibility testing dated from January to December 2016, from six locations comprising three hospitals and three private diagnostic service laboratories. The study locations include Trust Specialist Hospital (TH), Holy Trinity Medical Center (HTMC), LA General Hospital (LAGH), Patholab Solutions (Ghana) Limited (PSGL), G2 Medical Laboratory and Mediplast Diagnostic Center (G2ML). All locations are situated in the city of Accra, Ghana and the data were sampled from January to May 2017.

### Data extraction {#Sec5}

The clinical information extracted from the six laboratories included type of sample analyzed, name of pathogens isolated and the names of antibiotics used for susceptibility testing and the susceptibility results as recorded in the laboratory report. All information were confirmed by each laboratory technician and reconfirmed by the chief biomedical scientist.

### Laboratory analysis, clinical samples and collection of bacterial isolates {#Sec6}

Several types of clinical samples were cultured, including urine, blood, sputum, urethral smear, pus and seminal fluid, and swabs from various body sites (vagina, ear, throat, umbilical cord, eye and wound). All the laboratories sampled for the current study employed similar standard microbiological culturing techniques.

### Bacterial identification {#Sec7}

All the laboratories performed similar microscopic identification as previously described \[[@CR10]\]. For Gram-positive cocci, tube coagulase and catalase were done for species differentiation. Further biochemical tests included lactose fermentation, indole, citrate utilization, urease and Triple Sugar Iron reaction to ascertain the biochemical characteristics of the Gram-negative isolates. Two of the laboratories (Trust Hospital and Mediplast Diagnostic Center) also deployed the BBL Crystal Panel Viewer (Becton--Dickinson Maryland, USA) for further identification of isolates.

### Antimicrobial susceptibility {#Sec8}

Antimicrobial susceptibility test were performed by all 6 laboratories using the Kirby-Bauer disk diffusion method \[[@CR11]\] and interpreted using the Clinical Laboratory Standard Institute guidelines \[[@CR12]\]. Gram-positive and Gram-negative antibiotic disks were selected for Gram-positive and Gram-negative bacterial isolates, respectively. Each laboratory used disks manufactured by Abtek Biologicals, UK and Biomark Laboratories, India. The disks and their concentrations in micrograms included: ampicillin (AMP: 10), cotrimoxazole (COT: 25), amoxiclav (AMC: 20/10), nalidixic acid (NAL: 30), tetracycline (TET: 30), ceftriaxone (CTR: 30), ceftazidime (CAZ: 30), nitrofurantoin (NIT: 300), gentamicin (GEN: 10), ciprofloxacin (CIP: 30), levofloxacin (LEV: 5), norfloxacin (NOR: 30), chloramphenicol (CHL: 10), cefuroxime (CRX: 30), amikacin (AMK: 30), piperacillin (PIP: 100), nitrofurantoin (NTD: 200), cefotaxime (CTX: 30), penicillin (P: 1.5), flucloxacillin (FLX: 1), erythromycin (ERY: 5), amoxicillin (AMX: 30), ofloxacin (OF: 5), cloxacillin (CLX: 5), perfloxacin (PEF: 10), augmentin (AUG: 30), vancomycin (VAN: 30), meropenem (MEM: 10), roxithromycin (RO: 15), sparfloxacin (SPX: 5), lincomycin (LM: 15), azithromycin (AZM: 15), pipemidic acid (PPA: 20).

### Data analysis {#Sec9}

Collected data was entered into Microsoft Excel and loaded into statistical package for social sciences (SPSS, version 20) for analysis. Proportions of predominant isolates and antibiotic resistance profiles were compared using Chi square test. The Pearson correlation test was used to assess associations among locations and isolates in relation to the resistance profile of the isolates at a critical probability *P *\< 0.05.

Results {#Sec10}
-------

Records on resistant bacterial isolates and the antibiotic resistant profile cultured from January to December 2016 in six microbiology laboratories were extracted. These laboratories include three hospitals namely Trust Hospital (TH), LA General Hospital (LAGH) and Holy Trinity Medical Center (HTMC) and three private diagnostic service laboratories, Mediplast Diagnostic Center (MDC), Patholab Solutions Ghana Limited (PSGL) and G2 Medical Laboratory (G2ML).

In the study period, a total of 10,237 samples were cultured and 1701 (16.62%) resistant isolates were obtained. However, proportions of antibiotic resistant bacteria differed significantly from one laboratory to the other with PSGL samples generating the highest number of resistant isolates (33.08%, P \< 0.05), whereas isolates recovered at G2ML showed the lowest level of resistance (5.51%, P \< 0.05) (Table [1](#Tab1){ref-type="table"}).Table 1Comparison of antibiotic resistance between laboratories using Chi square testLaboratoriesNumber of isolatesResistant isolates (%)TH1515204 (13.47^d^)MDC24336 (14.81^d^)PSGL1058350 (33.08^a^)LAGH1302298 (22.89^c^)G2ML3978219 (5.51^e^)HTMC2141594 (27.74^b^)Proportions followed by different letters in a column means differences in proportion of resistant isolates at α \< 0.05%

Out of the six labs, nineteen different specimens were taken and statistical analysis revealed from all laboratories that urine samples are significantly more contaminated with antibiotic resistant bacteria than all other sample types (P \< 0.05, Additional file [1](#MOESM1){ref-type="media"}).

Samples were taken from female and male patients in all the six study areas but only three provided data on sex groups. A two by two comparison revealed for TH and LAGH that female gender is significantly associated with infection by antibiotic resistant bacteria compared to males (P \< 0.05, Table [2](#Tab2){ref-type="table"}). MDC had equal proportions (50%) of resistant bacteria from male and female patients (Table [2](#Tab2){ref-type="table"}).Table 2Repartition of resistant bacteria by sex of patientsLaboratoriesResistant isolatesP-valueFemales (%)Males (%)TH166 (81.37)38 (18.63)0.000001MDC18 (50)18 (50)0.8136LAGH207 (69.46)91 (30.54)0.000001*TH* Trust Hospital, *MDC* Mediplast Diagnostic Center, *LAGH* LA General Hospital

The predominant resistant bacterial species varied from one lab to the other, but *E. coli* and *Staphylococcus* were the main isolates from all the laboratories. From TH and G2ML, *E. coli* were the most recovered isolates (47.5%, n = 204 and 38.4%, n = 219, respectively). However, *S. aureus* prevailed in isolates recovered at MDC, PSGL and LAGH (22.2%, n = 36; 50.9%, n = 350 and 29.5%, n = 298, respectively). Undistinguished resistant Staphylococcus species were the most common isolates from HTMC (44.8%, n = 594) (Table [3](#Tab3){ref-type="table"}).Table 3Proportion of resistant bacterial species isolated from clinical samples from each laboratoryResistant isolatesTHMDCPSGLLAGHG2MLHTMCNumber (%)Number (%)Number (%)Number (%)Number (%)Number (%)*Providencia* spp.NRNRNRNRNR53 (8.9)*M. morganii*NRNRNRNRNR3 (0.5)*Citrobacter* spp.NR1 (2.8)1 (0.3)17 (5.7)23 (10.5)NR*S. aureus*21 (10.3)8 (22.2)178 (50.9)88 (29.5)28 (12.8)NR*Pseudomonas* spp.16 (7.8)3 (8.3)13 (3.7)29 (9.7)25 (11.4)7 (1.2)*S. epidermidis*3 (1.5)4 (11.1)1 (0.3)1 (0.3)6 (2.7)NR*K. pneumoniae*NR1 (2.8)NR1 (0.3)NRNR*P. aeruginosa*NR1 (2.8)3 (0.9)18 (6.0)14 (6.4)12 (2.0)*Enterobacter* spp.6 (2.9)5 (13.9)NR12 (4.0)3 (1.4)23 (3.9)*N. gonorrhoea*4 (2.0)2 (5.6)NRNR12 (5.5)NR*E. coli*97 (47.5)7 (19.4)120 (34.3)6.8 (22.8)84 (38.4)86 (14.5)*Y. pestis*NR1 (2.8)NRNRNRNR*S. pyogenes*NRNRNRNRNR2 (0.3)*Proteus* spp.5 (2.5)2 (5.6)7 (2.0)17 (5.7)NR4 (0.7)*Klebsiella* spp.25 (12.3)1 (2.8)4 (1.1)20 (6.7)1 (0.5)12 (2.0)*P. vulgaris*NRNR8 (2.3)NR1 (0.5)NR*S. saprophyticus*NRNR7 (2.0)6 (2.0)NRNR*E. faecalis*27 (13.2)NR7 (2.0)NRNRNR*P. mirabilis*NRNR1 (0.3)8 (2.7)2 (0.9)NR*Enterococcus* spp.NRNRNR6 (2.0)14 (6.4)31 (5.2)*Acinetobacter* spp.NRNRNR1 (0.3)1 (0.5)NR*Bacillus* spp.NRNRNR3 (1.0)NR1 (0.2)*Streptococcus* spp.NRNRNR2 (0.7)5 (2.3)NR*Salmonella* spp.NRNRNR1 (0.3)NRNR*Staphylococcus* spp.NRNRNRNRNR266 (44.8)*C. freundii*NRNRNRNRNR94 (15.8)*NR* not reported, *TH* Trust Hospital, *MDC* Mediplast Diagnostic Center, *PSGL* Patholab Solutions (Ghana) Limited, *LAGH* LA General Hospital, *G2ML* G2 Medical Laboratory Service, *HTMC* Holy Trinity Medical Centre

Records of the bacterial species and their resistance pattern can be found in Additional file [2](#MOESM2){ref-type="media"}. Here we summarized the antibiotic resistance profile of the three predominant resistant isolates from each laboratory. At TH, *E. coli*, *Enterococcus faecalis* and *Klebsiella* spp were resistant to AMP, COT, AMC, NAL, TET, CRO, GEN, LEV, NOR, CXM, NTD and CTZ at varying proportions. At MDC, *S. aureus, E. coli and Enterobacter* spp displayed resistance of varying degrees to AMP, COT, TET, CIP, NOR, CHL and CXM. Data from PSGL show that *S. aureus, E. coli and Pseudomonas* spp demonstrated resistance to CEF, PIP, CHL, CTX, AMK, GEN, NAL, CFT, AUG, CIP, TET, NIT, VAN, CTR, MEM, COT, ERY AMP and CRX. From LAGH, the predominant isolates (*S. aureus, E. coli and Pseudomonas* spp) were resistant to COT, CIP, GEN, AMP, MEM, TET, CRX, AMK, LEV, CTR and CTX. At G2ML *S. aureus, E. coli and Citrobacter* spp showed resistance against GEN, CIP, AMP, AUG, COT, CRX, TET, CFT, PIP, NAL, CTX, CTR and CHL. The three predominant isolates (*E. coli*, *Staphylococcus* spp and *Citrobacter freundi*) from HTMC were resistant to CPZ, CIP, CTR, PIP, CTX, TET, LEV, GEN, NX, AMK, NA, AMP, OF, CHL, CXM, COT, NIT, AMX, ERY, LM, RO and AZM with different proportions (Additional file [2](#MOESM2){ref-type="media"}).

Discussion {#Sec11}
----------

Antibiotic resistant bacterial infections have become a threat, in particular in developing countries, but to obtain an effective treatment plan, it is vital to have an overview of the current resistance level. In this study, data on culture and sensitivity results from six microbiology laboratories were extracted. Within the entire period, each of the six laboratories reported varying numbers of antibiotic resistant bacteria strains ranging from 36 to 594 resistant isolates. Statistical analysis revealed that samples from PSGL generated the highest proportions of resistant isolates (33.08%). There is therefore a possibility that patients living around or attending PSGL are likely to be more infected with antibiotic resistant bacteria, as it is situated in a densely populated area of residence, compared to patients who attended the other laboratories. Isolates recovered at G2ML, located in an area which primarily covers a business district, demonstrated the lowest level of antibiotic resistance as compared to the rest (5.51%). Among the six labs, 19 different types of clinical specimen were processed, but the highest level of antibiotic resistant bacteria was found in the urine samples in all laboratories. The proportions of resistant isolates ranged from 37.9% and up to 69.1%. High level resistance (66.7%) in urine has also been shown at the Korle-Bu Teaching Hospital in Ghana \[[@CR13]\]. In Sierra Leone 85.7% of multidrug resistant isolates were identified in urine specimen \[[@CR14]\]. Furthermore, the most prevailing resistant bacteria isolated from the various specimens in all the laboratories were *E. coli* and Staphylococcus. *E. coli* is the primary etiologic agent causing urinary tract infection, accounting for 90% of the cases \[[@CR15]\], however, in this study we did not acquire data on disease state of patients. But our data showed that female patients from TH (81.37%) and LAGH (69.46%) had the highest level of resistant bacteria compared to males. That significantly more resistant bacteria were found in female urine samples correlates with a higher susceptibility of infection in females than males, due to the physiological and anatomical differences. Resistant *Staphylococcus aureus* recovered from various specimens were found in the range 10.3--50.9%. The undistinguished *Staphylococcus* spp. (44.8%) from HTMC laboratory may be due to lack of special media or other requirements for accurate and definitive identification. High level antibiotic resistant *S. aureus* has previous been shown in other studies from Ghana and Ethiopia \[[@CR5], [@CR16], [@CR17]\]. Often, high levels of *S. aureus* are isolated from different sites of infection, probably due to the fact that this bacterium is part of the normal flora on skin and gut, but can infect breaches on the skin. Moreover, *S. aureus* is often found at the hospital settings, increasing the risk of infections. Due to the known risk of bacterial spread at hospitals, and lack of typing data, we cannot rule out that some of the resistant bacteria isolated from different specimen may in fact be the same clone.

Gram-negative bacteria accounted for 65.4% of the resistant bacteria, whereas Gram-positive accounted for 34.6%. Overall, *S. aureus*, *E. coli*, *Citrobacter* spp., *Pseudomonas* spp. and *Enterobacter* spp. from all the laboratories, showed high resistance against tetracycline, ampicillin and cotrimoxazole. Similar report of high resistance to these antibiotics in Ghana has previously been reported \[[@CR5], [@CR18]\]. They are also regarded as the most widely used antibiotics in developing countries, as they are considered inexpensive and generally have broad-spectrum activity \[[@CR19]\]. We also observed high resistance of *Klebsiella* spp. to ceftriaxone and cefuroxime, which has also been observed in a recent study from Rwanda \[[@CR20]\]. But the resistance to amoxiclav, amikacin and chloramphenicol was low across most of the laboratories except at G2ML where resistance towards amoxiclav (augmentin) was mostly high.

Conclusion {#Sec12}
----------

Our analysis of the culture and sensitivity test results of the various species of bacteria isolated from different clinical specimens at various microbiology laboratories revealed that high levels of resistant bacteria were recovered from urine specimens. Furthermore, resistant *E. coli* and *Staphylococcus* species were the most prevalent isolates recovered from all the specimens. Specimen from female patients presented the highest prevalence of resistant bacteria isolates as compared to male patients. We observed high resistance to tetracycline, ampicillin, cotrimoxazole and the cephalosporins, but low resistance to amoxiclav and the aminoglycosides. The variations in resistance pattern of the bacterial isolates across the laboratories suggests that regular surveillance and local susceptibility pattern is extremely important in selecting the most appropriate and effective antibiotic for the treatment of bacterial infections.

Limitations of the study {#Sec13}
========================

Our study have some limitations due to lack of information on the disease status of the patients, and it is possible that different specimens were collected from the same patient, resulting in isolation of the same bacterial species.

Additional files
================

 {#Sec14}

**Additional file 1.** Antibiotic resistant bacteria isolated from different sample types at the six laboratories. Total number and percentage of resistant bacterial isolates from each type of specimen isolated at TH (Trust Hospital); MDC (Mediplast Diagnostic Center); PSGL (Patholab Solutions Ghana Limited); LAGH (LA General Hospital); G2ML (G2 Medical Laboratory); HTMC (Holy Trinity Medical Center). **Additional file 2.** List of isolates and proportion (%) of resistance against each tested antibiotic. Data shown for each laboratory. Total list of all bacteria isolated at the six laboratories and the percentage of resistant bacteria against all tested antibiotics. TH (Trust Hospital); MDC (Mediplast Diagnostic Center); PSGL (Patholab Solutions Ghana Limited); LAGH (LA General Hospital); G2ML (G2 Medical Laboratory); HTMC (Holy Trinity Medical Center).
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MDC

:   Mediplast Diagnostic Center

PSGL

:   Patholab Solutions Ghana Limited

LAGH

:   LA General Hospital

G2ML

:   G2 Medical Laboratory

HTMC

:   Holy Trinity Medical Center

AMR

:   antimicrobial resistance

SPSS

:   statistical package for social sciences

AMP

:   ampicillin

COT

:   cotrimoxazole

AMC

:   amoxiclav

NAL

:   nalidixic acid

TET

:   tetracycline

CTR

:   ceftriaxone

CAZ

:   ceftazidime

NIT

:   nitrofurantoin

GEN

:   gentamicin

CIP

:   ciprofloxacin

LEV

:   levofloxacin

NOR

:   norfloxacin

CHL

:   chloramphenicol

CRX

:   cefuroxime

AMK

:   amikacin

PIP

:   piperacillin

NTD

:   nitrofurandantoin

CTX

:   cefotaxime

P

:   penicillin

FLX

:   flucloxacillin

ERY

:   erythromycin

AMX

:   amoxicillin

OF

:   ofloxacin

CLX

:   cloxacillin

PEF

:   perfloxacin

AUG

:   augmentin

VAN

:   vancomycin

MEM

:   meropenem

RO

:   roxithromycin

SPX

:   sparfloxacin

LM

:   lincomycin

AZM

:   azithromycin

PPA

:   pipemidic acid
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